Pub Date : 2021-07-01DOI: 10.4103/ijaai.ijaai_16_22
Raj Kumar, A. Mavi, S. Spalgais, M. Kumar, Kamal Singh, Priya
BACKGROUND: Asthma is a chronic disease that affects large number of people worldwide. In urban areas, asthmatic people are getting exposed to pigeon antigen (droppings and feathers) around the workplace and domestic areas. The present study was conducted to the determination of MUC1 protein in the blood of pigeon-exposed asthmatic patients by the high-performance liquid chromatography (HPLC) method. MATERIALS AND METHODS: This was a prospective study of 108 pigeon-exposed asthma patients. We enrolled 17 asthmatic patients for detection of MUC1 expression in their serum sample who were atopic and skin prick testing positive for pigeon antigens (droppings and feathers). The MUC1 analysis was done with HPLC method. RESULTS: A total of 17 asthmatic patients were enrolled on the basis of the history of pigeon exposure and positive skin prick test for pigeon's feather and dropping allergens including 9 males and 8 females, the average age of the study candidates was 28.8 ± 10.1 years. MUC1 concentration was raised in all of the asthmatic patients exposed to pigeons. The MUC1 was upregulated in 15 and downregulated in 2 patients. A higher concentration of MUC1 was seen in younger patients. CONCLUSION: Pigeon droppings and feathers allergen exposed and sensitivity showed the higher MUC1 expression in serum in asthma patients. The concentration of MUC1 was higher in the younger age group. The HPLC method was easier and economical for the detection of MUC1.
{"title":"Qualitative analysis of protein antigen in bird exposed asthma patients by high-performance liquid chromatography method","authors":"Raj Kumar, A. Mavi, S. Spalgais, M. Kumar, Kamal Singh, Priya","doi":"10.4103/ijaai.ijaai_16_22","DOIUrl":"https://doi.org/10.4103/ijaai.ijaai_16_22","url":null,"abstract":"BACKGROUND: Asthma is a chronic disease that affects large number of people worldwide. In urban areas, asthmatic people are getting exposed to pigeon antigen (droppings and feathers) around the workplace and domestic areas. The present study was conducted to the determination of MUC1 protein in the blood of pigeon-exposed asthmatic patients by the high-performance liquid chromatography (HPLC) method. MATERIALS AND METHODS: This was a prospective study of 108 pigeon-exposed asthma patients. We enrolled 17 asthmatic patients for detection of MUC1 expression in their serum sample who were atopic and skin prick testing positive for pigeon antigens (droppings and feathers). The MUC1 analysis was done with HPLC method. RESULTS: A total of 17 asthmatic patients were enrolled on the basis of the history of pigeon exposure and positive skin prick test for pigeon's feather and dropping allergens including 9 males and 8 females, the average age of the study candidates was 28.8 ± 10.1 years. MUC1 concentration was raised in all of the asthmatic patients exposed to pigeons. The MUC1 was upregulated in 15 and downregulated in 2 patients. A higher concentration of MUC1 was seen in younger patients. CONCLUSION: Pigeon droppings and feathers allergen exposed and sensitivity showed the higher MUC1 expression in serum in asthma patients. The concentration of MUC1 was higher in the younger age group. The HPLC method was easier and economical for the detection of MUC1.","PeriodicalId":53075,"journal":{"name":"Indian Journal of Allergy Asthma and Immunology","volume":"7 1","pages":"55 - 60"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87076442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.4103/ijaai.ijaai_28_21
P. Kathuria, M. Rai, G. Hassan
Hymenoptera venom hypersensitivity reaction affects about 3% of the general population and a higher percentage (14%–43%) in beekeepers. Bee venom immunotherapy (bVIT) is effective in reducing subsequent severe systemic reactions and has a significant beneficial effect on disease-specific quality of life in both children and adults. In patients with a history of recurrent systemic anaphylactic reaction with bee venom, successful bVIT is difficult to achieve and can often lead to withdrawal of treatment. The combination of bVIT and omalizumab is a good option for these patients. Omalizumab is a humanized nonanaphylactogenic monoclonal anti-immunoglobulin (Ig) E antibody against the Cε3 domain of IgE to reduce the allergenicity, if combined with bVIT. We describe a successful treatment with combined omalizumab and bVIT in a case of recurrent anaphylaxis by honey bee sting hypersensitivity. Herein, subcutaneous omalizumab 150 mg was started 15 days before the initiation of bVIT and subsequently once a month for 30 months along with cluster doses of bVIT till the cumulative dose of 100 μg was achieved successfully.
{"title":"Successful treatment with a combination of bee venom immunotherapy and omalizumab for recurrent anaphylaxis after honey bee sting","authors":"P. Kathuria, M. Rai, G. Hassan","doi":"10.4103/ijaai.ijaai_28_21","DOIUrl":"https://doi.org/10.4103/ijaai.ijaai_28_21","url":null,"abstract":"Hymenoptera venom hypersensitivity reaction affects about 3% of the general population and a higher percentage (14%–43%) in beekeepers. Bee venom immunotherapy (bVIT) is effective in reducing subsequent severe systemic reactions and has a significant beneficial effect on disease-specific quality of life in both children and adults. In patients with a history of recurrent systemic anaphylactic reaction with bee venom, successful bVIT is difficult to achieve and can often lead to withdrawal of treatment. The combination of bVIT and omalizumab is a good option for these patients. Omalizumab is a humanized nonanaphylactogenic monoclonal anti-immunoglobulin (Ig) E antibody against the Cε3 domain of IgE to reduce the allergenicity, if combined with bVIT. We describe a successful treatment with combined omalizumab and bVIT in a case of recurrent anaphylaxis by honey bee sting hypersensitivity. Herein, subcutaneous omalizumab 150 mg was started 15 days before the initiation of bVIT and subsequently once a month for 30 months along with cluster doses of bVIT till the cumulative dose of 100 μg was achieved successfully.","PeriodicalId":53075,"journal":{"name":"Indian Journal of Allergy Asthma and Immunology","volume":"27 1","pages":"94 - 98"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87927252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.4103/ijaai.ijaai_67_20
S. Rani, Aastha Agarwal
{"title":"Purpuric autologous serum skin test in urticaria: Is it mere a chance occurrence or a marker of strong autoimmunity","authors":"S. Rani, Aastha Agarwal","doi":"10.4103/ijaai.ijaai_67_20","DOIUrl":"https://doi.org/10.4103/ijaai.ijaai_67_20","url":null,"abstract":"","PeriodicalId":53075,"journal":{"name":"Indian Journal of Allergy Asthma and Immunology","volume":"38 1","pages":"106 - 107"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73808278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.4103/ijaai.ijaai_3_22
Kuldeepkumar Singh, T. Khandagale, Akshit Puri, Sangeeta Sinha
BACKGROUND: Hymenoptera venom allergy is one of the leading insect allergies in which allergens that promote IgE-mediated immune responses cause mild-to-severe reactions. Vespula germanica has a high spread rate and invades many regions of the world, while Vespa mandarinia has caused many fatalities in Asian countries including India. Ves g 5 and Vesp m 5 are important allergens of V. germanica and V. mandarinia, respectively, which cause allergenic reactions. AIM: This study aimed to predict the B- and T-cell epitopes of allergens Ves g 5 and Vesp m 5 using computational tools. MATERIALS AND METHODS: ProtParam, Jalview, and Swiss-Model analyzed the physiochemical, allergen sequence and 3D model. BepiPred-2.0, ABCPred, and ElliPro predicted B-cell epitopes, while Immune Epitope Database major histocompatibility complex-II binding prediction tool and CD4+ T-cell immunogenicity prediction tool were used to predict and confirm immunogenic T-cell epitopes RESULTS: Nine linear and four discontinuous B-cell epitopes were predicted for the Ves g 5 allergen and ten linear and five discontinuous B-cell epitopes were predicted for the Vesp m 5 allergen. Four and three T-cell epitopes were predicted for the allergens Ves g 5 and Vesp m 5, showing efficient binding and immunogenicity, respectively. CONCLUSION: Venom immunotherapy used as a treatment for HVA shows few fatal reactions and side effects, hence epitope-based vaccines or therapies are necessary. These results can be further used in the process of better immunotherapy and peptide-based vaccine design as well as to understand the etiology of Ves g 5 and Vesp m 5 allergens.
{"title":"In silico prediction of B-cell and T-cell epitope of Ves g 5 and Vesp m 5 allergens","authors":"Kuldeepkumar Singh, T. Khandagale, Akshit Puri, Sangeeta Sinha","doi":"10.4103/ijaai.ijaai_3_22","DOIUrl":"https://doi.org/10.4103/ijaai.ijaai_3_22","url":null,"abstract":"BACKGROUND: Hymenoptera venom allergy is one of the leading insect allergies in which allergens that promote IgE-mediated immune responses cause mild-to-severe reactions. Vespula germanica has a high spread rate and invades many regions of the world, while Vespa mandarinia has caused many fatalities in Asian countries including India. Ves g 5 and Vesp m 5 are important allergens of V. germanica and V. mandarinia, respectively, which cause allergenic reactions. AIM: This study aimed to predict the B- and T-cell epitopes of allergens Ves g 5 and Vesp m 5 using computational tools. MATERIALS AND METHODS: ProtParam, Jalview, and Swiss-Model analyzed the physiochemical, allergen sequence and 3D model. BepiPred-2.0, ABCPred, and ElliPro predicted B-cell epitopes, while Immune Epitope Database major histocompatibility complex-II binding prediction tool and CD4+ T-cell immunogenicity prediction tool were used to predict and confirm immunogenic T-cell epitopes RESULTS: Nine linear and four discontinuous B-cell epitopes were predicted for the Ves g 5 allergen and ten linear and five discontinuous B-cell epitopes were predicted for the Vesp m 5 allergen. Four and three T-cell epitopes were predicted for the allergens Ves g 5 and Vesp m 5, showing efficient binding and immunogenicity, respectively. CONCLUSION: Venom immunotherapy used as a treatment for HVA shows few fatal reactions and side effects, hence epitope-based vaccines or therapies are necessary. These results can be further used in the process of better immunotherapy and peptide-based vaccine design as well as to understand the etiology of Ves g 5 and Vesp m 5 allergens.","PeriodicalId":53075,"journal":{"name":"Indian Journal of Allergy Asthma and Immunology","volume":"21 1","pages":"72 - 81"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89467595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.4103/ijaai.ijaai_2_21
Navgeet Mathur, M. Mathur
This case report is about a 55-year-old female who presented with wandering unilateral edema in the sequence of the left breast (for 7 days) followed by left upper limb (for 1 month), followed by the left nape of the neck (for 1 day), followed by left scalp (for 1 day), followed by left-sided face (for 3 days), followed by right-sided face (for 2 days). Edema progressed from one site to another site in the above sequence with the overlapping period of only 12–24 h and later subsided completely from its previous site. In the patient's language edema was moving from site to site like a slow wave moving forward. The patient took multiple consultations but could not get any relief. The patient was evaluated according. Serum total eosinophil count found 3100/cumm (30.1% of total leucocyte count) and diagnosed with angioedema. The patient was completely recovered by steroid and antihistaminic. To the best of our knowledge, this is the first case reporting wandering unilateral edema like a wave.
{"title":"A rare and interesting case of wandering unilateral edema like a wave","authors":"Navgeet Mathur, M. Mathur","doi":"10.4103/ijaai.ijaai_2_21","DOIUrl":"https://doi.org/10.4103/ijaai.ijaai_2_21","url":null,"abstract":"This case report is about a 55-year-old female who presented with wandering unilateral edema in the sequence of the left breast (for 7 days) followed by left upper limb (for 1 month), followed by the left nape of the neck (for 1 day), followed by left scalp (for 1 day), followed by left-sided face (for 3 days), followed by right-sided face (for 2 days). Edema progressed from one site to another site in the above sequence with the overlapping period of only 12–24 h and later subsided completely from its previous site. In the patient's language edema was moving from site to site like a slow wave moving forward. The patient took multiple consultations but could not get any relief. The patient was evaluated according. Serum total eosinophil count found 3100/cumm (30.1% of total leucocyte count) and diagnosed with angioedema. The patient was completely recovered by steroid and antihistaminic. To the best of our knowledge, this is the first case reporting wandering unilateral edema like a wave.","PeriodicalId":53075,"journal":{"name":"Indian Journal of Allergy Asthma and Immunology","volume":"1 1","pages":"99 - 102"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80003385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.4103/ijaai.ijaai_9_21
K. Minni, G. Tharini
BACKGROUND: Chronic spontaneous urticaria (CSU) poses a therapeutic challenge by dermatologists and patients alike. OBJECTIVES: This study aimed to find the prevalence of functional autoantibodies among patients using autologous serum skin test (ASST) and to evaluate the efficacy of autologous serum therapy (AST) as an adjuvant in CSU. MATERIALS AND METHODS: An open-labeled, single-centered, prospective, interventional study of 1 year was performed after institutional ethical approval among 55 consenting patients of CSU. ASST was performed to find the prevalence of functional autoantibodies and those positive were given weekly intramuscular AST for the next 9 weeks. For clinical outcome, weekly urticaria activity score (UAS7) was recorded at baseline and at week 10. Any adverse effects were recorded. Wilcoxon sign-ranked test and Fisher's exact test were used to demonstrate equal variance. Results: Fifty-five CSU patients consented to participate in the study; 41 were ASST+ and six were dropped out; hence, the prevalence of autoreactivity was 74.54%. Four of seven who presented with angioedema were ASST+. Thus, the prevalence of angioedema in ASST+ patients of CSU was 11.4%. At the end of 10th week, on comparing individual components of UAS7, there was a statistical significant difference (P < 0.05) in the number of wheals (P = 0.00001), pruritus (P = 0.00001), frequency of wheals (P = 0.00001), as well as the overall UAS7 (P = 0.0001) scores. The effect size is 1.23 (Cohen's d). On grading the improvement at week 10, marked (>75%), good (50%–74%), satisfactory (25%–49%), and poor (<25%) improvement were observed in 8 (22.9%), 12 (34.3%), 11 (31.4%), and 4 (11.4%) patients, respectively. CONCLUSION: AST is effective in significantly reducing wheals and pruritus and improves quality of life. It can be tried as an adjuvant before switching patient to other immunosuppressants or expensive biologicals in this current COVID-19 pandemic. Large long-term prospective randomized controlled trials with follow-up are required to conclusively ascertain the efficacy of AST as an adjuvant in CSU.
{"title":"An open-labeled, single-centered, interventional, prospective study to determine the efficacy of autologous serum therapy in chronic spontaneous urticaria","authors":"K. Minni, G. Tharini","doi":"10.4103/ijaai.ijaai_9_21","DOIUrl":"https://doi.org/10.4103/ijaai.ijaai_9_21","url":null,"abstract":"BACKGROUND: Chronic spontaneous urticaria (CSU) poses a therapeutic challenge by dermatologists and patients alike. OBJECTIVES: This study aimed to find the prevalence of functional autoantibodies among patients using autologous serum skin test (ASST) and to evaluate the efficacy of autologous serum therapy (AST) as an adjuvant in CSU. MATERIALS AND METHODS: An open-labeled, single-centered, prospective, interventional study of 1 year was performed after institutional ethical approval among 55 consenting patients of CSU. ASST was performed to find the prevalence of functional autoantibodies and those positive were given weekly intramuscular AST for the next 9 weeks. For clinical outcome, weekly urticaria activity score (UAS7) was recorded at baseline and at week 10. Any adverse effects were recorded. Wilcoxon sign-ranked test and Fisher's exact test were used to demonstrate equal variance. Results: Fifty-five CSU patients consented to participate in the study; 41 were ASST+ and six were dropped out; hence, the prevalence of autoreactivity was 74.54%. Four of seven who presented with angioedema were ASST+. Thus, the prevalence of angioedema in ASST+ patients of CSU was 11.4%. At the end of 10th week, on comparing individual components of UAS7, there was a statistical significant difference (P < 0.05) in the number of wheals (P = 0.00001), pruritus (P = 0.00001), frequency of wheals (P = 0.00001), as well as the overall UAS7 (P = 0.0001) scores. The effect size is 1.23 (Cohen's d). On grading the improvement at week 10, marked (>75%), good (50%–74%), satisfactory (25%–49%), and poor (<25%) improvement were observed in 8 (22.9%), 12 (34.3%), 11 (31.4%), and 4 (11.4%) patients, respectively. CONCLUSION: AST is effective in significantly reducing wheals and pruritus and improves quality of life. It can be tried as an adjuvant before switching patient to other immunosuppressants or expensive biologicals in this current COVID-19 pandemic. Large long-term prospective randomized controlled trials with follow-up are required to conclusively ascertain the efficacy of AST as an adjuvant in CSU.","PeriodicalId":53075,"journal":{"name":"Indian Journal of Allergy Asthma and Immunology","volume":"138 1","pages":"88 - 93"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75360567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.4103/ijaai.ijaai_4_22
N. Krishna, Amita Nene, Mahavir Modi, Tanvir Reza, Ashwin Songara, V. Deshmukh
Asthma control is highly inadequate in India, with worse outcomes and poor adherence to inhaled corticosteroids (ICSs). As per the Global Initiative for Asthma guidelines, leukotriene receptor antagonist (LTRA) can be added when a low-to-moderate dose of ICS does not provide sufficient disease control. The combination of montelukast with its anti-inflammatory action and acebrophylline with its mild bronchodilator, anti-inflammatory, and mucolytic actions may be beneficial in patients with asthma. This manuscript aims to present an expert opinion to discuss the role of montelukast and acebrophylline combination in the management of asthma. An expert panel comprising nine specialists in respiratory medicine took part in a roundtable discussion to review the role of montelukast–acebrophylline combination in the management of asthma. A qualitative question-and-answer-based format was used to help facilitate the discussion. It was concurred that the montelukast and acebrophylline combination may be used if asthma symptoms remain uncontrolled with ICS and long-acting β2-agonists. This combination can also be preferred in patients with severe pulmonary obstruction along with allergic bronchopulmonary aspergillosis, in patients with asthma–chronic obstructive pulmonary disease overlap syndrome, and in patients with a history of smoking. There is adequate evidence for the role of montelukast and acebrophylline as individual drugs in asthma. However, evidence related to their combination therapy is lacking. The panel has reiterated the need for studies to evaluate the safety and efficacy of montelukast and acebrophylline combination in patients with asthma and its variants.
{"title":"Expert opinion on montelukast and acebrophylline combination in the management of asthma","authors":"N. Krishna, Amita Nene, Mahavir Modi, Tanvir Reza, Ashwin Songara, V. Deshmukh","doi":"10.4103/ijaai.ijaai_4_22","DOIUrl":"https://doi.org/10.4103/ijaai.ijaai_4_22","url":null,"abstract":"Asthma control is highly inadequate in India, with worse outcomes and poor adherence to inhaled corticosteroids (ICSs). As per the Global Initiative for Asthma guidelines, leukotriene receptor antagonist (LTRA) can be added when a low-to-moderate dose of ICS does not provide sufficient disease control. The combination of montelukast with its anti-inflammatory action and acebrophylline with its mild bronchodilator, anti-inflammatory, and mucolytic actions may be beneficial in patients with asthma. This manuscript aims to present an expert opinion to discuss the role of montelukast and acebrophylline combination in the management of asthma. An expert panel comprising nine specialists in respiratory medicine took part in a roundtable discussion to review the role of montelukast–acebrophylline combination in the management of asthma. A qualitative question-and-answer-based format was used to help facilitate the discussion. It was concurred that the montelukast and acebrophylline combination may be used if asthma symptoms remain uncontrolled with ICS and long-acting β2-agonists. This combination can also be preferred in patients with severe pulmonary obstruction along with allergic bronchopulmonary aspergillosis, in patients with asthma–chronic obstructive pulmonary disease overlap syndrome, and in patients with a history of smoking. There is adequate evidence for the role of montelukast and acebrophylline as individual drugs in asthma. However, evidence related to their combination therapy is lacking. The panel has reiterated the need for studies to evaluate the safety and efficacy of montelukast and acebrophylline combination in patients with asthma and its variants.","PeriodicalId":53075,"journal":{"name":"Indian Journal of Allergy Asthma and Immunology","volume":"49 1","pages":"48 - 54"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74596215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.4103/ijaai.ijaai_33_21
Mukesh Gupta, G. Basavaraj
Sulfites are commonly used preservatives and additives in the food and pharmaceutical industries. Many people develop adverse reactions to them which may vary from mild skin rash to life-threatening anaphylactic reactions. However, asthma exacerbation is the most commonly linked problem. The possibility of sulfite sensitivity should be considered when individuals demonstrate asthma symptoms following the consumption of sulfite-containing foods (such as dried fruits and wines in adults and packaged food in children such as biscuits, chips, and packaged drinks) or adverse skin reactions following the use of cosmetics or medicated creams. In fact, many of the mild-to-moderate asthma cases in children can be cured by just avoiding the packaged/preserved/processed food and beverages. Food that has no additives at all is to be preferred particularly if it is to be consumed by children. It is best to eat a preservative-free diet if at all possible by adults as well if required natural food preservatives should be used.
{"title":"Sulphites in food & drinks in asthmatic adults & children: What we need to know","authors":"Mukesh Gupta, G. Basavaraj","doi":"10.4103/ijaai.ijaai_33_21","DOIUrl":"https://doi.org/10.4103/ijaai.ijaai_33_21","url":null,"abstract":"Sulfites are commonly used preservatives and additives in the food and pharmaceutical industries. Many people develop adverse reactions to them which may vary from mild skin rash to life-threatening anaphylactic reactions. However, asthma exacerbation is the most commonly linked problem. The possibility of sulfite sensitivity should be considered when individuals demonstrate asthma symptoms following the consumption of sulfite-containing foods (such as dried fruits and wines in adults and packaged food in children such as biscuits, chips, and packaged drinks) or adverse skin reactions following the use of cosmetics or medicated creams. In fact, many of the mild-to-moderate asthma cases in children can be cured by just avoiding the packaged/preserved/processed food and beverages. Food that has no additives at all is to be preferred particularly if it is to be consumed by children. It is best to eat a preservative-free diet if at all possible by adults as well if required natural food preservatives should be used.","PeriodicalId":53075,"journal":{"name":"Indian Journal of Allergy Asthma and Immunology","volume":"8 1","pages":"43 - 47"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83719322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.4103/ijaai.ijaai_15_21
R. Kale, Raghavendra Khachhawaha
OBJECTIVE: Bronchial asthma is the most common chronic disease affecting children and young adults. The prevalence of asthma is on the rise worldwide with increasing levels of pollution. The epidemiology of asthma is a growing area of research. There is a paucity of data from central India, especially from Raipur, which has become the capital of Chattishgarh since the year 2000. This community-based study was conducted to estimate the prevalence of bronchial asthma in school going children aged between 6–7 years and 13–14 years. MATERIALS AND METHODS: A cross-sectional study using ISSAC questionnaires was conducted across 12 schools in Raipur, selected on a random basis. The required sample size of 1000/age group was needed according to International Study of Asthma and Allergies in Childhood criteria, so a total of 2029 children were recruited in both age groups. Data were managed in Microsoft Office Excel and were analyzed using tests of proportion. RESULT: Out of 2029 children evaluated, 153 (7.54%) had a positive history of wheezing throughout their lives and the relative number of wheezy girls was 7.56% as compared to boys 7.52%. Comparison between two age groups 6–7 and 13–14 years, wheezing incidence of 7.37% and 7.71% was similar with no significant difference. Confirmed asthma was detected in 2.32% of cases. No significant difference was noted in both age groups, i.e. 1.97% in 6–7 and 2.67% in 13–14 years. Higher incidence of exercise-induced wheeze was noted in older age group (13–14 years) children 5.04% versus 4.23%. CONCLUSION: The prevalence of bronchial asthma was 2.32% in children in Raipur. Increasing trends in prevalence due to increasing pollution needs environmental measure to control pollution.
{"title":"Estimation of prevalence of bronchial asthma in preschool and prepubertal children using international study of asthma and allergies in childhood criteria in Raipur Chhattisgarh","authors":"R. Kale, Raghavendra Khachhawaha","doi":"10.4103/ijaai.ijaai_15_21","DOIUrl":"https://doi.org/10.4103/ijaai.ijaai_15_21","url":null,"abstract":"OBJECTIVE: Bronchial asthma is the most common chronic disease affecting children and young adults. The prevalence of asthma is on the rise worldwide with increasing levels of pollution. The epidemiology of asthma is a growing area of research. There is a paucity of data from central India, especially from Raipur, which has become the capital of Chattishgarh since the year 2000. This community-based study was conducted to estimate the prevalence of bronchial asthma in school going children aged between 6–7 years and 13–14 years. MATERIALS AND METHODS: A cross-sectional study using ISSAC questionnaires was conducted across 12 schools in Raipur, selected on a random basis. The required sample size of 1000/age group was needed according to International Study of Asthma and Allergies in Childhood criteria, so a total of 2029 children were recruited in both age groups. Data were managed in Microsoft Office Excel and were analyzed using tests of proportion. RESULT: Out of 2029 children evaluated, 153 (7.54%) had a positive history of wheezing throughout their lives and the relative number of wheezy girls was 7.56% as compared to boys 7.52%. Comparison between two age groups 6–7 and 13–14 years, wheezing incidence of 7.37% and 7.71% was similar with no significant difference. Confirmed asthma was detected in 2.32% of cases. No significant difference was noted in both age groups, i.e. 1.97% in 6–7 and 2.67% in 13–14 years. Higher incidence of exercise-induced wheeze was noted in older age group (13–14 years) children 5.04% versus 4.23%. CONCLUSION: The prevalence of bronchial asthma was 2.32% in children in Raipur. Increasing trends in prevalence due to increasing pollution needs environmental measure to control pollution.","PeriodicalId":53075,"journal":{"name":"Indian Journal of Allergy Asthma and Immunology","volume":"114 1","pages":"17 - 21"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75299843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：